A tech executive used ChatGPT to help develop a personalized cancer vaccine for his terminally ill dog after conventional veterinary oncology offered little hope, according to The Australian. Faced with a grim prognosis, he turned to OpenAI's chatbot as a research tool to work through complex biomedical literature and identify viable treatment paths, eventually pursuing a neoantigen-based immunotherapy approach.
Neoantigen vaccines work by training the immune system to recognize and attack cancer cells based on their specific mutational signatures. The approach has been an active area of human oncology research for years — Moderna and Merck reported a 49% reduction in recurrence risk for high-risk melanoma patients in a 2023 Phase 2b trial of their mRNA neoantigen vaccine — but its use in veterinary medicine is rare. The executive reportedly used ChatGPT to accelerate his reading of the relevant literature, then coordinated with laboratories to produce a bespoke therapeutic for the animal.
The case draws attention to real gaps in oversight. When an individual commissions a custom biologic outside a clinical trial, there is no IRB review, no adverse event reporting, and no standardized protocol — concerns that apply whether the patient is human or animal. Dogs and humans share enough biology to make some oncology research transferable, but species differences in immune response, dosing, and tumor microenvironments mean results cannot be assumed to translate cleanly.
The original Australian report does not specify which version of ChatGPT was used or detail the outcome for the dog. Those gaps matter. Without knowing whether the vaccine had any measurable effect, the story is compelling but incomplete. The next development worth watching: whether veterinary oncology institutions begin formalizing LLM-assisted research protocols, or whether cases like this one prompt regulators to clarify where the lines sit for custom biologics developed with AI assistance.